12:01 PM EST, 12/05/2024 (MT Newswires) -- CG Oncology ( CGON ) said Thursday that topline data from its phase 3 trial in patients with high-risk non-muscle invasive bladder cancer, unresponsive to Bacillus Calmette Guerin, showed 74.5% achieved a complete response at any time following treatment with cretostimogene as a single agent.

No grade 3 or higher treatment-related adverse events or deaths were reported, the company said, adding that no patients discontinued cretostimogene due to treatment-related issues.

CG Oncology ( CGON ) shares were 7% lower in recent trading.

Price: 33.44, Change: -2.47, Percent Change: -6.88